DDAVP

Human medicines European public assessment report (EPAR): Veyvondi, vonicog alfa, Date of authorisation: 31/08/2018, Revision: 9, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, Marketing, Agency, INN, Allergy, ATC, Antibody, Plasma, Blood, DDAVP, International, Bleeding, Von Willebrand factor, Injection, Headache, Disease, Coagulopathy, Language, Hypersensitivity, European Medicines Agency, Von Willebrand disease, Select, Anatomy, IIA, VWD, Medical device

Human medicines European public assessment report (EPAR): Veyvondi, vonicog alfa, Date of authorisation: 31/08/2018, Revision: 9, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Veyvondi, vonicog alfa, Date of authorisation: 31/08/2018, Revision: 9, Status: Authorised

Global Von Willebrand Disease (VWD) Treatment Market Report 2023: Increasing Public Awareness Related to VWD Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, June 12, 2023
Biotechnology, Pharmaceutical, Health, Bleeding, VWD, Eagle, DDAVP, Type, Government, Lymphocytosis, Von Willebrand factor, VWF, Von Willebrand disease, Patient, Fibrin, Blood, Growth, Diagnosis, Rare, Research, FDA, Hormone replacement therapy, Pharmaceutical industry, Teva

On the basis of type of VWD, von Willebrand disease treatment market can be segmented as Type 1 VWD, Type 2 VWD and Type 3 VWD.

Key Points: 
  • On the basis of type of VWD, von Willebrand disease treatment market can be segmented as Type 1 VWD, Type 2 VWD and Type 3 VWD.
  • The types of therapeutic treatments used against von Willebrand disease are Desmopressin (DDAVP), hormone replacement therapy, contraceptives, anti-fibrinolytic or clot-stabilizing drugs, and fibrin sealants.
  • The key factor responsible for growth of von Willebrand disease is increasing public awareness related to VWD which is fueling the diagnosis rate in North America and Europe.
  • North America was observed as the largest market for von Willebrand disease treatment followed by Europe.

Bleeding Disorders Treatment Global Market Report 2022: Ukraine-Russia War Impact

Retrieved on: 
Tuesday, January 3, 2023
Organization, Liver disease, Takeda, Trauma, Octapharma, DDAVP, Patient, Von Willebrand disease, Pfizer, CSL Behring, University, World Federation of Hemophilia, Growth, Bleeding, Half-life, Shire (pharmaceutical company), COVID-19, Menstruation, Biomedical technology, Blood, AbbVie, Plasma, World government, DNA, Coagulopathy, Hormone replacement therapy, Biogen, Takeda Pharmaceutical Company, Ferring Pharmaceuticals, University of Oslo, Bayer, Geography, Novartis, VIII, Hospital, Novo Nordisk, Pharmaceutical industry, Birth control, Medical device, Haemophilia

The bleeding disorders treatment market is expected to grow to $18.50 billion in 2026 at a CAGR of 7.9%.

Key Points: 
  • The bleeding disorders treatment market is expected to grow to $18.50 billion in 2026 at a CAGR of 7.9%.
  • The regions covered in the bleeding disorders treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The bleeding disorders treatment market research report is one of a series of new reports that provides Bleeding disorders treatment market statistics, including bleeding disorders treatment industry global market size, regional shares, competitors with bleeding disorders treatment market share, detailed Bleeding disorders treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the bleeding disorders treatment industry.
  • This bleeding disorders treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Acquired Hemophilia Treatment Global Market Report 2022: Focus on Product Pipeline Remains the Key Focus Among Market Players - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 30, 2022
Health, Pharmaceutical, Patient, Haemophilia, Ageing, National Organization for Rare Disorders, NORD, Medicine, Incidence, National Organization of Short Statured Adults, Intelligence, DDAVP, Hospital, Factor VIII, VII, VIII, CAGR, Population, Bleeding, APCC, Degenerative disease, Efficiency, Renewable energy, Medical imaging, Healthcare

The "Acquired Hemophilia Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acquired Hemophilia Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030" report has been added to ResearchAndMarkets.com's offering.
  • Medical practitioners warn that acquired hemophilia can cause life-threatening bleeding complications in severe cases.
  • The acquired hemophilia treatment market is anticipated to grow at a CAGR of 3.25% during the forecast period of 2022-2030.
  • After scrutiny of the global acquired hemophilia treatment market, the regional trends, market sizes, and the overall growth paired with the latest and anticipated events, North America is observed to be the most dominant regional market for acquired hemophilia treatment.

Octapharma shares new data at ISTH 2022 in its mission to meet the challenges faced by people with bleeding disorders

Retrieved on: 
Monday, July 4, 2022
Efficacy, Von Willebrand disease, Product, Critical care, Head, DDAVP, Patient, Atomic mass, III, VWF, Adult, International Society on Thrombosis and Haemostasis, Factor VIII, Pharmacokinetics, Spotlight, Female, Gold, VIII, Plasma, Thrombosis, Awareness, Woman, Risk, Bleeding, Pensioner, BST, Immunotherapy, Haemophilia, RNA, Fondaparinux, Quality of life, Coagulopathy, VWD, PTP, Congress, Epitope, International Society, ISTH, Dietary supplement, Vaccine, Pharmaceutical industry, Birth control, Bookkeeping, Factor VIII (medication), Octapharma, Symposia, Safety

The data will be featured in eleven poster presentations and two Supported Symposia during this major international meeting.

Key Points: 
  • The data will be featured in eleven poster presentations and two Supported Symposia during this major international meeting.
  • Octapharma is proud to be a Gold Supporter of the ISTH 2022 Congress.
  • Safety and pharmacokinetics of a subcutaneous recombinant FVIII (OCTA101) in adult patients with severe haemophilia A. Presenting Author: Sigurd Knaub
    PB0559.
  • "Despite advances in the field, managing emergency bleeding and bleeding disorders still comes with considerable challenges.

Octapharma shares new data at ISTH 2022 in its mission to meet the challenges faced by people with bleeding disorders

Retrieved on: 
Monday, July 4, 2022
Efficacy, Von Willebrand disease, Product, Critical care, Head, DDAVP, Patient, Atomic mass, III, VWF, Adult, International Society on Thrombosis and Haemostasis, Factor VIII, Pharmacokinetics, Spotlight, Female, Gold, VIII, Plasma, Thrombosis, Awareness, Woman, Risk, Bleeding, Pensioner, BST, Immunotherapy, Haemophilia, RNA, Fondaparinux, Quality of life, Coagulopathy, VWD, PTP, Congress, Epitope, International Society, ISTH, Dietary supplement, Vaccine, Pharmaceutical industry, Birth control, Bookkeeping, Factor VIII (medication), Octapharma, Symposia, Safety

The data will be featured in eleven poster presentations and two Supported Symposia during this major international meeting.

Key Points: 
  • The data will be featured in eleven poster presentations and two Supported Symposia during this major international meeting.
  • Octapharma is proud to be a Gold Supporter of the ISTH 2022 Congress.
  • Safety and pharmacokinetics of a subcutaneous recombinant FVIII (OCTA101) in adult patients with severe haemophilia A. Presenting Author: Sigurd Knaub
    PB0559.
  • "Despite advances in the field, managing emergency bleeding and bleeding disorders still comes with considerable challenges.